Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Skuli

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Cell Cycle (Georgetown, Tex.)|October 7, 2009
HIF-1alpha versus HIF-2alpha in endothelial cells and vascular functions: is there a master in angiogenesis regulation?Nicolas Skuli, M Celeste Simon
Cell Metabolism|January 4, 2011
The tumor suppressor LKB1 emerges as a critical factor in hematopoietic stem cell biologyBryan Krock, Nicolas Skuli, M Celeste Simon
Molecular Cell|October 7, 2019
Even Cancer Cells Watch Their Cholesterol!Romain Riscal, Nicolas Skuli, M Celeste Simon
Genes & Cancer|August 7, 2012
Hypoxia-induced angiogenesis: good and evilBryan L Krock, Nicolas Skuli, M Celeste Simon
Cancer & Metabolism|February 6, 2022
Glucagon signaling via supraphysiologic GCGR can reduce cell viability without stimulating gluconeogenic gene expression in liver cancer cellsJason Godfrey, Romain Riscal, Nicolas Skuli, et al.
Molecular Cancer Research : MCR|January 12, 2021
Cell-Intrinsic Tumorigenic Functions of PPARγ in Bladder Urothelial CarcinomaDanielle J Sanchez, Rindert Missiaen, Nicolas Skuli, et al.
Molecular Metabolism|June 6, 2018
PPARγ is dispensable for clear cell renal cell carcinoma progressionDanielle J Sanchez, David J Steger, Nicolas Skuli, et al.
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Metformin and Cancer, an Ambiguanidous RelationshipSarah J Skuli, Safwan Alomari, Hallie Gaitsch, et al.
Oncotarget|October 6, 2017
Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimenRichard E Kast, Nicolas Skuli, Georg Karpel-Massler, et al.
Nature Metabolism|March 24, 2021
Glycogen metabolism is dispensable for tumour progression in clear cell renal cell carcinomaHong Xie, Jun Song, Jason Godfrey, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Cell Cycle (Georgetown, Tex.)|October 7, 2009
HIF-1alpha versus HIF-2alpha in endothelial cells and vascular functions: is there a master in angiogenesis regulation?Nicolas Skuli, M Celeste Simon
Cell Metabolism|January 4, 2011
The tumor suppressor LKB1 emerges as a critical factor in hematopoietic stem cell biologyBryan Krock, Nicolas Skuli, M Celeste Simon
Molecular Cell|October 7, 2019
Even Cancer Cells Watch Their Cholesterol!Romain Riscal, Nicolas Skuli, M Celeste Simon
Genes & Cancer|August 7, 2012
Hypoxia-induced angiogenesis: good and evilBryan L Krock, Nicolas Skuli, M Celeste Simon
Cancer & Metabolism|February 6, 2022
Glucagon signaling via supraphysiologic GCGR can reduce cell viability without stimulating gluconeogenic gene expression in liver cancer cellsJason Godfrey, Romain Riscal, Nicolas Skuli, et al.
Molecular Cancer Research : MCR|January 12, 2021
Cell-Intrinsic Tumorigenic Functions of PPARγ in Bladder Urothelial CarcinomaDanielle J Sanchez, Rindert Missiaen, Nicolas Skuli, et al.
Molecular Metabolism|June 6, 2018
PPARγ is dispensable for clear cell renal cell carcinoma progressionDanielle J Sanchez, David J Steger, Nicolas Skuli, et al.
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Metformin and Cancer, an Ambiguanidous RelationshipSarah J Skuli, Safwan Alomari, Hallie Gaitsch, et al.
Oncotarget|October 6, 2017
Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimenRichard E Kast, Nicolas Skuli, Georg Karpel-Massler, et al.
Nature Metabolism|March 24, 2021
Glycogen metabolism is dispensable for tumour progression in clear cell renal cell carcinomaHong Xie, Jun Song, Jason Godfrey, et al.
Pageof 7